The Form 4 filing, a report of an insider's stock trades, was filed on November 18, 2026. The sales took place two days earlier. It lists Marshall Urist as Royalty Pharma plc's executive vice president for research and investments.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 25,000 |
| Price | $69.50 |
| Total Transaction Value | $1,737,490.29 |
| Insider | |
| Ticker Symbol | RPRX |
| Company | Royalty Pharma plc |
| Insider Name | Urist Marshall |
| Insider Title | EVP, Research & Investments |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 125,000 |
| Position Size Change | 16.67% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported with transaction code S. The filing covers two sale transactions by Marshall Urist.
What was the average price of the transaction?
The average price was $69.50 per share, rounded from $69.49961168. That average covers the 25,000 shares sold across both transactions. Separate prices for each sale are not available in the provided details.
How did this transaction affect the insider's holdings?
Marshall Urist sold 25,000 shares and reported owning 125,000 shares afterward. The shares sold were 16.67% of his reported shares before the sales. Those figures show a reported balance of 150,000 shares before the sales.
What's the total transaction value?
The two sales had a total value of $1,737,490.29, rounded to the nearest cent. That amount covers both transactions together.
Are there any special circumstances around this transaction?
The filing information includes a Rule 10b5-1 trading-plan reference. These plans set trading instructions ahead of time. The available details do not show whether that reference covers both sales or only part of the filing. Footnote text and plan terms are not available, so the plan's start date and trading schedule remain unknown.
For research purposes only; not investment advice.